Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer

Lv, Zhongchuan; Fan, Yongsheng; Chen, Hongbing; Zhao, Debin

doi:10.1007/s13277-014-2760-9

Cited by 82 publications

(46 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although increasing number of miRNAs have been identified as potential biomarkers for the early diagnosis of CRC 204, 209–211 , it seems unrealistic that a single miRNA will adequately capture the underlying disease heterogeneity in colorectal polyps and cancers. Accordingly, several studies have proposed combining miRNAs into a biomarker panel to improve the detection accuracy of colorectal neoplasms 212–215 .…”

Section: Noncoding Rnasmentioning

confidence: 99%

Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers

2015

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a leading cause of cancer deaths worldwide. One of the fundamental processes driving the initiation and progression of CRC is the accumulation of a variety of genetic and epigenetic changes in colon epithelial cells. Over the past decade, major advances have been made in our understanding of cancer epigenetics, particularly regarding aberrant DNA methylation, microRNA (miRNA) and noncoding RNA deregulation, and alterations in histone modification states. Assessment of the colon cancer “epigenome” has revealed that virtually all CRCs have aberrantly methylated genes and altered miRNA expression. The average CRC methylome has hundreds to thousands of abnormally methylated genes and dozens of altered miRNAs. As with gene mutations in the cancer genome, a subset of these epigenetic alterations, called driver events, is presumed to have a functional role in CRC. In addition, the advances in our understanding of epigenetic alterations in CRC have led to these alterations being developed as clinical biomarkers for diagnostic, prognostic and therapeutic applications. Progress in this field suggests that these epigenetic alterations will be commonly used in the near future to direct the prevention and treatment of CRC.

show abstract

Section: Noncoding Rnasmentioning

confidence: 99%

Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers

2015

View full text Add to dashboard Cite

show abstract

“…The manuscripts reported the down-regulation of miR-155 in the blood of patients with coronary artery disease [13,14], ischemic stroke [15], or type 2 DM [16]; upregulation in blood [17] and down-regulation in serum of patients with rheumatoid arthritis (RA) [18]; down-regulation in the serum of patients with lung cancer [19]; upregulation in the plasma of patients with lung cancer [20]; up-regulation in the serum of patients with colorectal cancer [21]; and up-regulation in the serum of patients with breast cancer [22]. Results reported for miR-155 were inconsistent: one study [19] showed dysregulation of miR-155 in the serum but constant levels in the plasma whereas another study [20] indicated up-regulation of this miRNA in the plasma of patients with lung cancer.…”

Section: Specificity Of Single Mirnasmentioning

confidence: 99%

Specific miRNA Disease Biomarkers in Blood, Serum and Plasma: Challenges and Prospects

2016

View full text Add to dashboard Cite

Significant effort has been devoted to discovering microRNA (miRNA) disease biomarkers. In particular, miRNAs in whole blood or specific blood components are candidates for improving the diagnosis of diseases, including life-threatening pathologies. This review covers the challenges crucial for the translation of miRNAs in body fluids (circulating miRNAs) from a research setting into a clinical care scenario. First, we discuss the specificity of miRNA biomarkers for the diagnosis of a disease. While single miRNAs such as miR-20a, miR-21, miR-155, and miR-126 are frequently not disease specific, miRNA signatures that consist of a plurality of different miRNAs may help to improve differentiation between pathologies. Second, we discuss the degree of reproducibility and highlight selected validation studies. While single miRNA markers are often confirmed by independent studies, miRNA signatures are less frequently verified. Third, we address challenges to the profiling of miRNAs in high-throughput settings and we discuss the appropriateness of various analytical platforms and bioinformatics towards a clinical application of miRNAs. Finally, we shed light on the suitability of enriched miRNA sources, e.g. fractionation of body fluids for extracellular vesicles such as exosomes or blood cells, to develop miRNA signatures. With an increasing number of verified miRNA signatures and with the advance of matured medium-throughput approaches in clinical settings, specific miRNA markers are increasingly likely to contribute to human healthcare.

show abstract

“…miRNA molecules are important regulators in development, normal physiology, and diseases. Moreover, some miRNA molecules have become biomarkers for diseases (38,39). Using bioinformatics, we have discovered that miR-214 is an upstream regulator gene of ABCB1.…”

Section: Discussionmentioning

confidence: 99%

Decreased expression of microRNA‑214 contributes to imatinib mesylate resistance of chronic myeloid leukemia patients by upregulating ABCB1 gene expression

Jin¹,

Yao²,

Fang³

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

The aim of the present study was to determine the expression of adenosine triphosphate binding cassette subfamily B member 1 (ABCB1) gene and its protein P-glycoprotein (PGP) in bone marrow mononuclear cells from chronic myeloid leukemia (CML) patients with imatinib mesylate (IM) resistance, or IM-resistant CML K562 cells. In addition, the molecular mechanism of action of microRNA (miR)-214 on ABCB1 in IM resistance was investigated. A total of 26 CML patients with IM resistance were included in the present study. In addition, 31 CML patients who did not have IM resistance were included as the control group. Bone marrow was collected from all subjects. The K562R cell line, which is a K562 cell line with IM resistance, was used for cellular studies. Reverse transcription-quantitative polymerase chain reaction was used to determine the expression of ABCB1 mRNA and miR-214 in cells. Western blotting was employed to determine the expression of PGP. Dual luciferase reporter assay was carried out to identify interactions between ABCB1 mRNA and miR-214. MTT assay was used to determine the survival rate of cells. ABCB1 mRNA and PGP expression was upregulated in bone marrow mononuclear cells from CML patients with IM resistance. K562R cells had higher ABCB1 and PGP expression than K562 cells, potentially due to their different sensitivity to IM. Expression miR-214 was decreased in bone marrow mononuclear cells from patients with IM resistance and K562R cells. Notably, miR-214 was able to bind with the 3′-untranslated region, seed region of ABCB1 mRNA to regulate its expression. In addition, elevated expression of miR-214 restored IM sensitivity to K562R cells potentially by affecting ABCB1 expression. The present study demonstrated that upregulated expression of ABCB1 mRNA and PGP in bone marrow mononuclear cells from CML patients with IM resistance may be associated with the downregulation of miR-214. In addition, miR-214 may participate in the IM resistance of CML patients by regulating ABCB1 expression.

show abstract

Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer

Cited by 82 publications

References 28 publications

Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers

Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers

Specific miRNA Disease Biomarkers in Blood, Serum and Plasma: Challenges and Prospects

Decreased expression of microRNA‑214 contributes to imatinib mesylate resistance of chronic myeloid leukemia patients by upregulating ABCB1 gene expression

Contact Info

Product

Resources

About